The Journal of Allergy and Clinical Immunology, July 2013, Vol.132(1), pp.242-244
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.jaci.2012.12.1571 Byline: Jonathan E. Phillips (a), Ruoqi Peng (a), Paul Harris (a), Lisa Burns (a), Lorena Renteria (a), Lennart K.A. Lundblad (b), Jay S. Fine (a), Carla M.T. Bauer (a), Christopher S. Stevenson (a) Author Affiliation: (a) Inflammation Discovery, pRED, Hoffmann-La Roche, Inc, Nutley, NJ (b) Vermont Lung Center, University of Vermont, Burlington, Vt Article Note: (footnote) Disclosure of potential conflict of interest: C. S. Stevenson, J. E. Phillips, R. Peng, P. Harris, L. Burns, L. Renteria, and C. M. T. Bauer are employed by Hoffmann-La Roche. L. K. A. Lundblad has received grants from Hoffman-La Roche and Merck, has consultant arrangements with Pfizer, is employed by the University of Vermont, and has received payment for the development of educational presentations from Jackson Labs. J. S. Fine is Executive Vice President of Boehringer Ingelheim Corporation.
View record in ScienceDirect (Access to full text may be restricted)